Currency In USD
| Previous Close | 4.61 |
| Open | 4.67 |
| Day High | 4.72 |
| Day Low | 3.99 |
| 52-Week High | 7.55 |
| 52-Week Low | 2.93 |
| Volume | 5.45M |
| Average Volume | 2.65M |
| Market Cap | 509.58M |
| PE | -6.25 |
| EPS | -0.65 |
| Moving Average 50 Days | 4.71 |
| Moving Average 200 Days | 4.29 |
| Change | -0.55 |
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 09, 2026 8:01 PM GMT
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science an
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science a